We aim to get in touch within one business day
Disclaimer: I consent to my data being processed for the purpose of responding to my inquiry and in accordance with the Roche Global Privacy Policy & Privacy Notice for Pharmacovigilance
Bring the potential of ROZLYTREK® to life
ROZLYTREK is well tolerated and has a manageable and consistent safety profile in both adult and paediatric patients1
ROZLYTREK is well tolerated and has a manageable and consistent safety profile in both adult and paediatric patients1
ROZLYTREK safety was evaluated in 504 adults and paediatric patients across multiple biomarkers and tumour types as an integrated analysis of four clinical trials: ALKA-372-001. STARTRK-1, STARTRK-2 and STARTRK-NG1
The majority of adverse reactions were manageable2
This medicinal product is subject to additional monitoring. This will allow quick identification of new safety information. Healthcare professionals are asked to report any suspected adverse reactions. See section 4.8 of the SmPC for details on how to report adverse reactions.
Footnotes
ALT, alanine aminotransferase; AST, aspartate aminotransferase; QT, time from the start of the Q wave to the end of the T wave; QTc, the corrected QT interval; TRAE, treatment-related adverse event.
References